ReviewCardiorenal medicine2020
Weathering the Cytokine Storm in COVID-19: Therapeutic Implications.
Review in Cardiorenal medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 2 syntheses or guidelines pooled it, 113 citations in OpenAlex.
- Pooled it
- Renal Injury by SARS-CoV-2 Infection: A Systematic Review.Kidney diseases (Basel, Switzerland) · 2021Pooled it
- Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia.Frontiers in immunology · 2021Trial
- Increased interleukin-6 and macrophage chemoattractant protein-1 are associated with respiratory failure in COVID-19.Scientific reports · 2020Trial
- A Case of Sudden Unexpected Infant Death with Presumptive SARS-CoV-2 Infection.International journal of molecular sciences · 2026Article
- Genetic variations in AAK1 and ADAM17 associated with circulatory cytokines changes influence COVID-19 susceptibility and severity.Human genomics · 2026Article
- Anti-Inflammatory Cytokine Profiles in Thrombotic Thrombocytopenic Purpura-Differences Compared to COVID-19.International journal of molecular sciences · 2024Article
- Immune Stimulation with Imiquimod to Best Face SARS-CoV-2 Infection and Prevent Long COVID.International journal of molecular sciences · 2024Review
- Review
- Association of the C3953T (rs1143634) variant of the interleukin 1 beta gene with the features of a complicated course of COVID-19-associated pneumonia.Molecular biology reports · 2024Article
- Role of epinephrine in attenuating cytokine storm, decreasing ferritin, and inhibiting ferroptosis in SARS-CoV-2.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2024Article
- Efficacy of the Cytokine Adsorption Therapy in Patients with Severe COVID-19-Associated Pneumonia: Lesson Learned from a Prospective Observational Study.Blood purification · 2024Observational
- Clinical Trials of Mesenchymal Stem Cells for the Treatment of COVID 19.Current stem cell research & therapy · 2024Review
- Global Perspective on COVID-19 Therapies, Cardiovascular Outcomes, and Implications for Long COVID: A State-of-the-Art Review.Journal of community hospital internal medicine perspectives · 2024Review
- Association of Delirium and Depression with Respiratory and Outcome Measures in COVID-19 Inpatients.Journal of personalized medicine · 2023Article
- Lithium Therapy in COVID-19 with Bipolar Affective Disorder-A Case Series.Indian journal of psychological medicine · 2023Article
- Physiological Basis for Using Vitamin D to Improve Health.Biomedicines · 2023Article
- Cellular and Molecular Mechanisms of Pathogenic and Protective Immune Responses to SARS-CoV-2 and Implications of COVID-19 Vaccines.Vaccines · 2023Review
- Zymosan Particle-Induced Hemodynamic, Cytokine and Blood Cell Changes in Pigs: An Innate Immune Stimulation Model with Relevance to Cytokine Storm Syndrome and Severe COVID-19.International journal of molecular sciences · 2023Article
- Expression of IFN-Gamma is significantly reduced during severity of covid-19 infection in hospitalized patients.PloS one · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recently emerged in Wuhan, Hubei-China, as responsible for the coronavirus disease 2019 (COVID-19) and then spread rapidly worldwide. While most individuals remain asymptomatic or develop only mild symptoms, approximately 5% develop severe forms of COVID-19 characterized by acute respiratory distress syndrome (ARDS) and multiple-organ failure (MOF) that usually require intensive-care support and often yield a poor prognosis. SUMMARY: The pathophysiology of COVID-19 is far from being completely understood, and the lack of effective treatments leads to a sense of urgency to develop new therapeutic strategies based on pathophysiological assumptions. The exaggerated cytokine release in response to viral infection, a condition known as cytokine release syndrome (CRS) or cytokine storm, is emerging as the mechanism leading to ARDS and MOF in COVID-19, thus endorsing the hypothesis that properly timed anti-inflammatory therapeutic strategies could improve patients' clinical outcomes and prognosis. Key Messages: The objective of this article is to explore and comment on the potential role of the promising immunomodulatory therapies using pharmacological and nonpharmacological approaches to overcome the dysregulated proinflammatory response in COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.